{"id":48993,"date":"2025-11-25T20:22:55","date_gmt":"2025-11-25T12:22:55","guid":{"rendered":"https:\/\/flcube.com\/?p=48993"},"modified":"2025-11-25T20:22:56","modified_gmt":"2025-11-25T12:22:56","slug":"zelgens-zg006-wins-btd-for-neuroendocrine-carcinoma-as-first-dll3-trispecific","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48993","title":{"rendered":"Zelgen&#8217;s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that <strong>ZG006<\/strong>, the world\u2019s first <strong>trispecific antibody targeting DLL3 (DLL3\/DLL3\/CD3)<\/strong>, received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for single\u2011agent treatment of <strong>advanced neuroendocrine carcinoma (NEC)<\/strong> in DLL3\u2011positive patients who progressed after platinum\u2011based therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>ZG006 (DLL3\/DLL3\/CD3 trispecific antibody)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Suzhou Zelgen Biopharmaceuticals (688266.SH)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced DLL3\u2011positive NEC post platinum therapy<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>FDA and NMPA approved for clinical trials<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First\u2011in\u2011class trispecific DLL3 format globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Trispecific antibody targeting <strong>DLL3 on tumor cells<\/strong> and <strong>CD3 on T\u2011cells<\/strong>, redirecting immune cells to kill NEC cells<\/li>\n\n\n\n<li><strong>Preclinical Data:<\/strong> Demonstrated <strong>significant tumor suppression<\/strong> in mouse models, with <strong>complete regression<\/strong> in a substantial proportion, indicating potent tumor\u2011killing effects<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Unique <strong>DLL3\/DLL3\/CD3<\/strong> format may overcome resistance and improve specificity vs. bispecific competitors<\/li>\n\n\n\n<li><strong>Pipeline Status:<\/strong> Part of Zelgen\u2019s <strong>First\u2011in\u2011Class<\/strong> pipeline in solid tumors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China NEC Incidence<\/strong><\/td><td>~<strong>12,000\u201115,000<\/strong> new cases annually<\/td><\/tr><tr><td><strong>DLL3\u2011Positive Share<\/strong><\/td><td>~70\u201180% of NEC patients (8,400\u201112,000 eligible)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Platinum\u2011based chemo; no approved targeted therapies<\/td><\/tr><tr><td><strong>Peak Sales Forecast (ZG006)<\/strong><\/td><td><strong>\u00a52.0\u20113.0\u202fbillion<\/strong> (~$280\u2011410\u202fmillion) by 2032<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>40\u201150% of eligible DLL3\u2011positive patients<\/td><\/tr><tr><td><strong>Competition<\/strong><\/td><td><strong>Amgen\u2019s tarlatamab<\/strong> (DLL3 bispecific) in Phase\u202f3 for SCLC; ZG006\u2019s trispecific format offers potential differentiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Next Catalyst:<\/strong> Phase\u202fI dose\u2011escalation data expected <strong>Q3\u202f2026<\/strong>; BTD status accelerates NMPA review timeline<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Dual FDA\/NMPA approval enables <strong>simultaneous development<\/strong>; potential for <strong>global partnership<\/strong> similar to other Chinese biotechs<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Reinforces Zelgen\u2019s position as a <strong>leader in novel antibody engineering<\/strong>, building on its successful JAK inhibitor portfolio<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ZG006\u2019s clinical development, regulatory pathway, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, competitive dynamics, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688266_20251125_LWFC.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20251125_LWFC.\"><\/object><a id=\"wp-block-file--media-2ade3990-f415-4f92-9fff-d28d33b2c999\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688266_20251125_LWFC.pdf\">688266_20251125_LWFC<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688266_20251125_LWFC.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2ade3990-f415-4f92-9fff-d28d33b2c999\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world\u2019s first trispecific antibody&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48995,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,905,2790,246],"class_list":["post-48993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-sha-688266","tag-t-cell-engager","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen&#039;s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world\u2019s first trispecific antibody targeting DLL3 (DLL3\/DLL3\/CD3), received Breakthrough Therapy Designation (BTD) from China\u2019s National Medical Products Administration (NMPA) for single\u2011agent treatment of advanced neuroendocrine carcinoma (NEC) in DLL3\u2011positive patients who progressed after platinum\u2011based therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48993\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen&#039;s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world\u2019s first trispecific antibody targeting DLL3 (DLL3\/DLL3\/CD3), received Breakthrough Therapy Designation (BTD) from China\u2019s National Medical Products Administration (NMPA) for single\u2011agent treatment of advanced neuroendocrine carcinoma (NEC) in DLL3\u2011positive patients who progressed after platinum\u2011based therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48993\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T12:22:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T12:22:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen&#8217;s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific\",\"datePublished\":\"2025-11-25T12:22:55+00:00\",\"dateModified\":\"2025-11-25T12:22:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504-1.webp\",\"keywords\":[\"Breakthrough therapy\",\"SHA: 688266\",\"T cell engager\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48993#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48993\",\"name\":\"Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504-1.webp\",\"datePublished\":\"2025-11-25T12:22:55+00:00\",\"dateModified\":\"2025-11-25T12:22:56+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world\u2019s first trispecific antibody targeting DLL3 (DLL3\\\/DLL3\\\/CD3), received Breakthrough Therapy Designation (BTD) from China\u2019s National Medical Products Administration (NMPA) for single\u2011agent treatment of advanced neuroendocrine carcinoma (NEC) in DLL3\u2011positive patients who progressed after platinum\u2011based therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48993\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48993#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen&#8217;s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world\u2019s first trispecific antibody targeting DLL3 (DLL3\/DLL3\/CD3), received Breakthrough Therapy Designation (BTD) from China\u2019s National Medical Products Administration (NMPA) for single\u2011agent treatment of advanced neuroendocrine carcinoma (NEC) in DLL3\u2011positive patients who progressed after platinum\u2011based therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48993","og_locale":"en_US","og_type":"article","og_title":"Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world\u2019s first trispecific antibody targeting DLL3 (DLL3\/DLL3\/CD3), received Breakthrough Therapy Designation (BTD) from China\u2019s National Medical Products Administration (NMPA) for single\u2011agent treatment of advanced neuroendocrine carcinoma (NEC) in DLL3\u2011positive patients who progressed after platinum\u2011based therapy.","og_url":"https:\/\/flcube.com\/?p=48993","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-25T12:22:55+00:00","article_modified_time":"2025-11-25T12:22:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48993#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48993"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen&#8217;s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific","datePublished":"2025-11-25T12:22:55+00:00","dateModified":"2025-11-25T12:22:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48993"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48993#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504-1.webp","keywords":["Breakthrough therapy","SHA: 688266","T cell engager","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48993#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48993","url":"https:\/\/flcube.com\/?p=48993","name":"Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48993#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48993#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504-1.webp","datePublished":"2025-11-25T12:22:55+00:00","dateModified":"2025-11-25T12:22:56+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world\u2019s first trispecific antibody targeting DLL3 (DLL3\/DLL3\/CD3), received Breakthrough Therapy Designation (BTD) from China\u2019s National Medical Products Administration (NMPA) for single\u2011agent treatment of advanced neuroendocrine carcinoma (NEC) in DLL3\u2011positive patients who progressed after platinum\u2011based therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48993#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48993"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48993#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504-1.webp","width":1080,"height":608,"caption":"Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48993#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen&#8217;s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48993"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48993\/revisions"}],"predecessor-version":[{"id":48996,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48993\/revisions\/48996"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48995"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}